Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual Congress

Plugin JSON Content Importer Pro not running: Check Licence! Check that a Licence is active for https://freeline.life
You might also like
Freeline Shareholders Approve Acquisition by Syncona
Freeline Presents Positive New Data from Phase 1/2 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease, in Late-Breaking Oral Presentation at ASGCT 27th Annual Meeting
Freeline Reports Updated Data From Phase 1/2 B-AMAZE Trial in Hemophilia B
Freeline Announces Expansion of Executive Leadership
Freeline Reports New Data from Fabry Disease Program, Pipeline and Company Updates, Including Appointment of Pamela Foulds, MD as Chief Medical Officer, and Third Quarter 2021 Financial Results
Freeline Granted ILAP Designation in United Kingdom by MHRA for FLT201, an Investigational Gene Therapy for the Treatment of Gaucher Disease
Get in touch

+44 (0)1438 906870
contact@freeline.life

Follow us on our social channels